scRNA-seq identified SRGN as a pan-cellular marker of aggressiveness, with tumor cell subclusters, LVECt, and HSCs showing stage-dependent upregulation during metastasis, directly aligning with advanced clinical phenotypes. The gene discussed is SRGN; the disease is neoplasm.